Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06308159
PHASE1/PHASE2

An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia

Sponsor: Lantu Biopharma

View on ClinicalTrials.gov

Summary

This is an interventional study to evaluate the safety and efficacy of autologous Hematopoietic Stem and Progenitor Cells (HSPCs) transduced with lentiviral vector encoding functional hemoglobin subunit beta (HBB) gene in patients with transfusion-dependent beta-thalassemia.

Official title: An Open-label Clinical Trial of Ex Vivo Beta-globin Lentiviral Vector Transduction of Autologous CD34+HSPCs (Vebeglogene Autotemcel) for the Treatment of Transfusion Dependent Beta-thalassemia Patients

Key Details

Gender

All

Age Range

Any - 35 Years

Study Type

INTERVENTIONAL

Enrollment

6

Start Date

2024-05-11

Completion Date

2027-08-01

Last Updated

2025-11-25

Healthy Volunteers

No

Interventions

DRUG

Vebeglogene autotemcel

Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.

Locations (2)

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Kunming, Yunnan, China

Kunming Hope of Health Hospital

Kunming, Yunnan, China